ClinicalTrials.gg
RecruitingNCT06456541Updated Oct 15, 2026

Infant Formula in Infants and Children With Cow's Milk Allergy

An interventional study of Experimental Extensively Hydrolyzed Formula and Placebo Extensively Hydrolyzed Formula in Cow's Milk Allergy, sponsored by Abbott Nutrition. Recruiting at 9 sites in United States. Open to participants aged 3 Months to 12 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Abbott Nutrition (part of Abbott) · Not applicable, Interventional, and Other

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.
Updated Oct 15, 2026Site recruiting status changedGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
3 Months to 12 Years
Sex
All
01

Study summary

This is a multi-center, randomized, double-blinded, placebo-controlled food challenge to be conducted in infants and children with confirmed IgE-mediated cow's milk allergy (CMA), followed by a 7-day open feeding of the experimental formula.

02

Conditions studied

  • Cow's Milk Allergy

Browse trials for

03

In context

Milk Hypersensitivity

147 studies on the registry are indexed under Milk Hypersensitivity; 26 are open to participants now.

This study's planned enrollment of 96 is above the median of 68 across 95 interventional studies indexed under Milk Hypersensitivity.

Browse Milk Hypersensitivity studies →

Lead sponsor

Abbott Nutrition is the lead sponsor of 156 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Months to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant's parent(s) is/are willing for their child to undergo confirmatory testing or must have had at least one of the following within 6 months of enrollment:

    1. Physician diagnosis of IgE-mediated CMA, according to the participant's clinical history (e.g. gastrointestinal symptoms, hives, respiratory symptoms or angioedema) AND, detectable serum milk-specific IgE >0.7 kUᴀ/L or positive skin prick test wheal ≥5 mm;
    2. Documentation of milk-specific serum IgE ≥15 kUᴀ/L or ≥ 5 kUᴀ/L if younger than 1 year;
    3. Documented cow's milk skin prick test wheal ≥8mm;
    4. Physician-supervised oral food challenge that elicited immediate, objective, allergic symptoms.
  • Participant's parent(s) agree for their child to stop oral use within 14 days and antihistamine use within 7 days prior to confirmation of diagnosis and food challenges.
  • Participant had followed a strict cow's milk protein-free diet for at least 2 weeks prior to enrollment.
  • Parent(s) confirm their intention not to administer any products containing cow's milk protein during the study.
  • Participant is between 3 months and 12 years of age at enrollment.
  • Participant's parent(s) has voluntarily signed and dated an Form (ICF), approved by an Independent Ethics Committee/Institutional Review Board (IEC/IRB) and provided Health Insurance Portability and Accountability Act (HIPAA) (or other applicable privacy regulation) authorization prior to any participation in the study.

Exclusion criteria

Exclusion Criteria:

  • Participant is partially or exclusively breastfed at the time of enrollment.
  • Participant is consuming an amino acid-based formula due to failure on an extensively hydrolyzed formula.
  • Significant chronic medical diseases including major chromosomal or congenital anomalies, gastrointestinal diseases, or abnormalities other than CMA, immunodeficiencies, unstable asthma, eczema and/or food allergies treated with biologics (omalizumab or other monoclonal antibody), FPIES, eosinophilic esophagitis, and severe uncontrolled eczema.
  • Previous severe anaphylactic reaction to cow's milk within the last two years.,
  • An adverse medical history or current condition that is thought by the investigator to have potential for effects on tolerance or the hypoallergenicity test.
  • Participant has an allergy or intolerance to any ingredient in the study product, as reported by the parent.
  • Participant is consuming baked milk products.
  • Use of and/or changing dose of high potency .
  • Participant is treated with any oral immunotherapy (sublingual, subcutaneous, and epicutaneous) for any food allergy.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
96 participants (estimated)

Study arms

  • Experimental
    Experimental Extensively Hydrolyzed Formula

    Administered during food challenge and at home feeding period of 7 days

    Other: Experimental Extensively Hydrolyzed Formula

  • Placebo comparator
    Placebo Extensively Hydrolyzed Formula

    Administered during food challenge

    Other: Placebo Extensively Hydrolyzed Formula

Interventions

  • OtherExperimental Extensively Hydrolyzed Formula

    Experimental powder formula

  • OtherPlacebo Extensively Hydrolyzed Formula

    Placebo powder formula

06

What researchers measure

Primary outcomes

  1. Food Challenge Reactions

    Percent of positive food challenge reactions to the experimental formula administered to cow's milk allergic infants and children.

    Time frame: Food Challenge 1 to Food Challenge 2 (within 14 days of the Food Challenge 1) (followed by 7 days of feeding the experimental formula at home.)

Secondary outcomes

  1. Volume of Experimental Formula Intake

    Parent completed diaries of Intake

    Time frame: Home Feeding Day 1 to Day 7

  2. Food Intake during Study

    Parent completed daily food diaries

    Time frame: Home Feeding Day 1 to Day 7

  3. Gastrointestinal Symptoms

    Parent completed diaries

    Time frame: Home Feeding Day 1 to Day 7

  4. Medication Use

    Parent completed diaries

    Time frame: Home Feeding Day 1 to Day 7

  5. Food Challenge Positive Reactions

    Percent of positive food challenge reactions to the experimental formula

    Time frame: Home Feeding Day 1 to Day 7

07

Study locations

8 of 9 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

1 registry update since Sep 25, 2026
Sites
Phoenix Children's is now Recruiting
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Phoenix Children's is now Recruiting
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06456541
Lead sponsor
Abbott Nutrition
Responsible party
Sponsor
First posted
Jun 13, 2024
Start date
Oct 1, 2024
Primary completion
Jul 2028 (estimated)
Completion
Jan 2029 (estimated)
Last update
Oct 15, 2026

Study contacts

Kristen DeLuca
Contact
kristen.deluca@abbott.com
6145653522
Jane Schlezinger
Contact
jane.schlezinger@abbott.com
+44 (0) 1628 77355

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion